Page last updated: 2024-12-07
coumarin 3,4-epoxide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
coumarin 3,4-epoxide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 126771 |
SCHEMBL ID | 3366275 |
MeSH ID | M0197953 |
Synonyms (12)
Synonym |
---|
coumarin 3,4-epoxide |
SCHEMBL3366275 |
1a,7b-dihydrooxireno[2,3-c]chromen-2-one |
2h-oxireno(c)(1)benzopyran-2-one, 1a,7b-dihydro- |
143873-69-2 |
mkj2db9drs , |
unii-mkj2db9drs |
DTXSID20932132 |
1a,7b-dihydro-2h-oxireno[c][1]benzopyran-2-one |
3,6-dioxatricyclo[5.4.0.0,2,4]undeca-1(11),7,9-trien-5-one |
EN300-22980934 |
Z3847441191 |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
"Coumarin, a natural product and fragrance ingredient, is a well recognized rat liver toxicant, and dietary administration at toxic dosages increased the incidence of rat cholangiocarcinomas and parenchymal liver-cell tumors in a chronic bioassay." | ( In vitro kinetics of coumarin 3,4-epoxidation: application to species differences in toxicity and carcinogenicity. Born, SL; Caudill, D; Lehman-McKeeman, LD; Smith, BJ, 2000) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 5 (83.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |